Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The hypothalamic-neurohypophyseal system in preeclampsia: a systematic review with a subgroup meta-analysis of copeptin levels worldwide.

Frontiers in endocrinology·2026
Same author

Pre-pregnancy body mass index classification and weight gain according to new brazilian protocols and their association with gestational diabetes mellitus.

Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia·2026
Same author

Adnexal Endometrioid Carcinomas With Sex Cord-Like Morphology are Frequently PAX8-Negative, SOX17-Positive, and Enriched for CTNNB1 Alterations.

The American journal of surgical pathology·2026
Same author

DICER1 -Related Primitive Polyphenotypic Neoplasm : A Report of 15 Cases of an Underrecognized Tumor of the Gynecologic Tract and Peritoneum.

The American journal of surgical pathology·2026
Same author

Routine Postpartum Colostrum Expression and Breastfeeding Outcomes in Women With Diabetes: A Feasibility Trial.

Journal of human lactation : official journal of International Lactation Consultant Association·2026
Same author

Efficacy of Combined Cervical Pessary and Progesterone in Women at High-Risk of Preterm Birth.

Diagnostics (Basel, Switzerland)·2026

Related Experiment Video

Updated: Jun 9, 2026

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas
05:31

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas

Published on: January 26, 2024

Inflammatory mediators gene polymorphisms in preeclampsia.

Camila S Franchim1, Nelson Sass, Rosiane Mattar

  • 1Department of Obstetrics, Sao Paulo Federal University, Sao Paulo, Brazil.

Hypertension in Pregnancy
|September 8, 2010
PubMed
Summary

Genetic variations in key inflammatory mediators, including IL-1R1, IL-12, IL-18, TLR-2, and TLR-4, were investigated for their association with preeclampsia (PE). This study found no significant link between these specific gene polymorphisms and the development of PE.

Related Experiment Videos

Last Updated: Jun 9, 2026

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas
05:31

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas

Published on: January 26, 2024

Area of Science:

  • Genetics
  • Immunology
  • Obstetrics

Background:

  • Preeclampsia (PE) is a serious pregnancy complication with complex etiology.
  • Inflammatory mediators play a role in PE pathogenesis.
  • Gene polymorphisms in inflammatory pathways are potential risk factors for PE.

Purpose of the Study:

  • To investigate the association between specific gene polymorphisms of proinflammatory mediators and preeclampsia.
  • To analyze polymorphisms in IL-1R1, IL-12, IL-18, TLR-2, and TLR-4 in relation to PE risk.

Main Methods:

  • Genotyping was performed on 109 preeclamptic patients and 174 healthy controls.
  • Chi-squared or Fisher's exact tests were used to compare genotype frequencies.
  • The control group was matched for race with the study group.

Main Results:

  • No significant differences in genotypic or allelic distributions were observed for any of the six analyzed polymorphisms between preeclamptic patients and controls.
  • Specific p-values for IL-1R1, IL-12, IL-18, TLR-2, and TLR-4 polymorphisms indicated no statistical association with PE.

Conclusions:

  • The investigated gene polymorphisms in IL-1R1, IL-12, IL-18, TLR-2, and TLR-4 are not associated with preeclampsia.
  • These specific genetic variations do not appear to be risk factors for developing PE.